You are about to leave
ALK Pro UK

You have selected a link that will take you to an external site. Click ‘cancel’ to return to ALK’s site or ‘continue’ to proceed.

September 2025
GB-NPR-2500036

This website is intended for UK healthcare professionals only. Adverse Event Reporting is at the bottom of the page.
Visit patient’s website
[mo_oauth_login]
Register

GRAZAX®

75,000 SQ-T sublingual lyophilizate

A complete overview of GRAZAX® can be found in the Summary of Product Characteristics (SmPC) which can be viewed below. A downloadable Patient Leaflet and the Prescribing Information (PI) and Adverse Event reporting can also be found on the links below.

View SmPC
Patient resources – patient leaflet
Prescribing information and adverse event reporting

GRAZAX® is a disease modifying sublingual immunotherapy tablet for the treatment of grass pollen induced rhinitis and conjunctivitis in adults and children (5 years or older), with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen.1

Patients taking GRAZAX® should primarily expect mild to moderate local allergic reactions to occur early in therapy that tend to subside spontaneously within 1 to 7 days. The most reported adverse reactions are oral pruritus, throat irritation and oedema mouth.

For the majority of events, the reaction should be expected to start within 5 minutes after intake of GRAZAX® on each day of occurrence and abate after minutes to hours.1

When to start with GRAZAX®?

Clinical effect on allergic rhinitis caused by grass pollen and conjunctivitis in the grass pollen season is expected if treatment starts at least 4 months before the expected start of the grass pollen season and is continued throughout the season. If the treatment starts 2-3 months before the season, some efficacy can also be achieved.1

Grass pollen season2

Contraindications and special warnings1

Asthma is a known risk factor for severe systemic allergic reactions. Patients with severe asthma or uncontrolled asthma (in adults: FEV1<70% of a predicted value after adequate pharmacological treatment, in children FEV1<80% of a predicted value after adequate pharmacological treatment) should not be treated with GRAZAX®.1 In addition, there are contraindications in patients with malignant or systemic conditions that affect the immune system (for example, autoimmune diseases, immune complex reactions or immune deficiencies).1
In case of severe systemic reactions, angioedema, difficulty swallowing, difficulty breathing, voice changes, hypotension or a feeling of a full throat, the doctor should be contacted immediately. In such cases, treatment should be stopped or postponed until a further date on the advice of the doctor.1

September 2026
GB-TBL-2600039

  1. GRAZAX® SmPC, GRAZAX 75,000 SQ-T sublingual lyophilisate – Summary of Product Characteristics (SmPC) – (emc) | 315;
  2. University of Worcester. (n.d.) Pollen calendar. Available at: Pollen Calendars by area – University Of Worcester (Accessed: September 2026)